Michelle Hudson

Research Project Manager

m.hudson@exeter.ac.uk

+44 (0) 1392 408181

RILD Building 2.15

University of Exeter Medical School, RILD Building, RD&E Hospital Wonford, Barrack Road, Exeter, EX2 5DW, UK

Overview

Michelle joined the NIHR Exeter Clinical Research Facility (CRF) and CBS as Research Project Manager in 2010. Her role entails working up and managing research studies (often multi-centred) for academics using the CRF or CTU, from concept to full study and beyond.
Michelle currently manages diabetes research studies, including the EXE-T1D study of extremely early-onset Type 1 diabetes (funded by Diabetes UK and the Helmsley Charitable Trust) and the MUGGLE study of stimulated glucagon as a biomarker of hypglycaemic risk in Type 1 diabetes (funded by the Helmsley Charitable Trust).
She managed the EU-funded DIRECT Consortium Type 2 Diabetes Progression study and two ‘recruit by genotype’ studies exploring the role of genetic variation on insulin secretion and sensitivity defects (DIVA), and improving our understanding of how fat in the body works (fATDIVA), with the aim of identifying why some people develop Type 2 diabetes. Previous studies include: the UNITED Project (funded by Wellcome Trust/Dept of Health), a 3 year multi-centre study that tested a complete care pathway for the appropriate diagnosis and treatment of young-onset diabetes; and the MRC-ABPI ProMASTER study looking at drug response to specific second- and third-line classes of treatment for Type 2 diabetes. These studies successfully met their objectives and will lead to several important publications and further research.

Prior to joining the UEMS, Michelle worked as a primary school teacher with a particular interest in Science, Design & Technology, English and PE. Her career began in medical publishing in London before moving to the west country.

If contacting with sensitive or personal information, please use: michelle.hudson4@nhs.net

Qualifications

BSc (Southampton)
2003 Qualified Teacher Status

Career

2010 – Present: Research Project Manager, University of Exeter College of Medicine and Health, and NIHR Exeter Clinical Research Facility

Class Teacher (with additional Teaching and Learning Responsibilities)
Partner and founder of Bougham Trout Farm
Health Sciences Promotions Manager - W.B. Saunders and Baillière Tindall (medical and nursing publishers)

Research

Research interests

Michelle currently manages research in different types and aspects of diabetes, hypglycaemic risk, and genetic variants that may influence insulin production and processing. In the future, her role can be applied across other areas of medical and experimental research.

Research projects

EXE-T1D (EXtremely Early-onset Type 1 Diabetes) - DUK & Helmsley Charitable Trust funded (CI: Prof Richard Oram)
MUGGLE (Stimulated glucagon as a biomarker of hypglycaemic risk) - Helmsley Charitable Trust funded (CI: Prof Richard Oram)
Microbio (The effect of dietary nitrate on the oral microbiota, markers of nitric oxide bioavailability and cardiovascular health in young and older adults) - BBSRC funded (CI: Prof Andrew Jones)
DIVA (DIabetes VAriants) – MRC funded (CI: Prof T Frayling)
fATDIVA (for Adipose Tissue DIabetes VAriants – ERC funded (CI: Prof T Frayling)
DIRECT T2D Progression – EU DIRECT Consortium (CI: Prof M Walker)
ProMASTER – MRC funded (CI: Prof A Hattersley)
UNITED – Wellcome Trust/DoH funded (CI: Prof A Hattersley)

Research networks

UK Trial Managers Network (UKTMN)

Exeter Clinical Trials Support Network (ECTSN)

Publications

Journal articles

Peters J, Anderson R, Shields B, Hudson M, Shepherd M, McDonald T, Hattersley A, Hyde C (In Press). Strategies to Identify Individuals with Monogenic Diabetes: Results of an Economic Evaluation. BMJ Open

Johnson M, Patel K, De Franco E, McDonald T, Hudson M, Dobbs R, Ellard S, Flanagan S, Hattersley A, Oram R, et al (In Press). Type 1 Diabetes can present before the age of 6 months and is characterised by autoimmunity and rapid loss of beta-cells. Diabetologia

Wyatt RC, Hagopian WA, Roep BO, Patel KA, Resnick B, Dobbs R, Hudson M, EXE-T1D Consortium, De Franco E, Ellard S, et al (2022). Congenital beta cell defects are not associated with markers of islet autoimmunity, even in the context of high genetic risk for type 1 diabetes. Diabetologia, 65(7), 1179-1184. Abstract. Author URL.

Koivula RW, Forgie IM, Kurbasic A, Viñuela A, Heggie A, Giordano GN, Hansen TH, Hudson M, Koopman ADM, Rutters F, et al (2019). Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia, 62(9), 1601-1615. Abstract. Author URL.

Wilman HR, Parisinos CA, Atabaki-Pasdar N, Kelly M, Thomas EL, Neubauer S, Jennison C, Ehrhardt B, Baum P, Schoelsch C, et al (2019). Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration. Journal of Hepatology, 71(3), 594-602. Abstract.

Shah N, Coathup V, Teare H, Forgie I, Giordano GN, Hansen TH, Groeneveld L, Hudson M, Pearson E, Ruetten H, et al (2019). Motivations for data sharing—views of research participants from four European countries: a DIRECT study. European Journal of Human Genetics, 27(5), 721-729. Abstract.

Shah N, Coathup V, Teare H, Forgie I, Giordano GN, Hansen TH, Groeneveld L, Hudson M, Pearson E, Ruetten H, et al (2019). Sharing data for future research—engaging participants’ views about data governance beyond the original project: a DIRECT Study. Genetics in Medicine, 21(5), 1131-1138. Abstract.

Shepherd MH, Shields BM, Hudson M, Pearson ER, Hyde C, Ellard S, Hattersley AT, Patel KA, UNITED study (2018). A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin. Diabetologia, 61(12), 2520-2527. Abstract. Author URL.

Shields B, McDonald T, Oram R, Hill A, Hudson M, Leete P, Pearson E, Richardson S, Morgan N, Hattersley A, et al (2018). C-peptide decline in type 1 diabetes has two phases: an initial exponential fall and a subsequent stable phase. Diabetes Care

Clissold RL, Fulford J, Hudson M, Shields BM, McDonald TJ, Ellard S, Hattersley AT, Bingham C (2018). Exocrine pancreatic dysfunction is common in hepatocyte nuclear factor 1β-associated renal disease and can be symptomatic. Clin Kidney J, 11(4), 453-458. Abstract. Author URL.

Shields B, Shepherd M, Hudson M, McDonald T, Colclough K, Peters J, Knight B, Hyde C, Ellard S, Pearson E, et al (2017). Population-based assessment of a biomarker-based screening pathway to aid diagnosis of monogenic diabetes in young-onset patients. Diabetes Care

Shepherd M, Shields B, Hammersley S, Hudson M, McDonald TJ, Colclough K, Oram RA, Knight B, Hyde C, Cox J, et al (2016). Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population with Monogenic Diabetes. Diabetes Care, 39(11), 1879-1888. Abstract. Author URL.

Oram RA, McDonald TJ, Shields BM, Hudson MM, Shepherd MH, Hammersley S, Pearson ER, Hattersley AT, UNITED Team (2015). Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors. Diabetes Care, 38(2), 323-328. Abstract. Author URL.

Teaching

Clinical Trials CSC3008

Edit Profile